Opthea to present at HC Wainwright BIOCONNECT Virtual Conference | Technology


MELBOURNE, Australia, January 04, 2022 (GLOBE NEWSWIRE) – Opthea Limited (ASX: OPT), a clinical-stage biopharmaceutical company developing new therapies to treat widespread and progressive retinal diseases, today announced that Dr. Megan Baldwin, Chief Executive Officer, will attend the HC Wainwright BIOCONNECT conference, which will be held virtually January 10-13, 2022.

The pre-recorded presentation will be available from Monday, January 10 at 7:00 a.m. ET (11:00 p.m. AET), and can be viewed on the Investors page of Opthea’s website at https://www.opthea.com/presentations/.

About Opthéa Limitée

Opthea (ASX: OPT; Nasdaq: OPT) is a biopharmaceutical company developing novel therapies to address unmet needs in the treatment of widespread and progressive retinal diseases, including age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s product candidate OPT-302 is currently in pivotal Phase 3 clinical trials and is under development for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of VEGF-A. the VEGF family, with the aim of improving overall efficacy and demonstrating greater vision gains than can be achieved by inhibiting VEGF-A alone.

Risks inherent in investing in biotechnology companies

There are a number of inherent risks associated with the development of pharmaceuticals to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug before it is marketed, and a significant proportion of drugs do not meet one or both of these criteria. Other risks include the uncertainty of patent and property rights protection, whether patent applications and granted patents will provide adequate protection to allow product development, obtaining necessary approvals from drug regulatory authorities. and the difficulties caused by rapid advances in technology. Companies like Opthea depend on the success of their research and development projects and their ability to attract funding to support these activities. Investment in research and development projects cannot be evaluated on the same fundamentals as commercial and manufacturing companies. Therefore, investing in companies specializing in drug development should be viewed as highly speculative. Opthea strongly recommends seeking professional investment advice before making such investments.

Authorized to broadcast on ASX by Megan Baldwin, CEO and Managing Director

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 E-mail: [email protected] Web: www.opthea.com

Copyright 2022 GlobeNewswire, Inc.


Comments are closed.